MoneyAM MoneyAM
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Research   Share Price   Awards   Indices   Market Scan   Company Zone   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Stock Screener   Forward Diary   Forex Prices   Director Deals   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Videos   Comparison Tables   Spread Betting   Broker Notes   Shares Magazine 
You are NOT currently logged in

 
Filter Criteria  
Epic: Keywords: 
From: Time:  (hh:mm) RNS:  MonAM: 
To: Time:  (hh:mm)
Please Note - Streaming News is only available to subscribers to the Active Level and above
 


RNS News Service

I confirm that I am accessing this story in my capacity as a private investor and NOT for professional purposes.

Form 38.5(b) - Willis Towers Watson PLC- Amendment

RNS

RNS Number : 9774C
Goldman Sachs & Co. LLC
22 October 2020
 

Amendment - due to the amendment of Equity transactions, the disclosure made on 20 October for dealings on 19 October has been updated. Sections 2(a) and 3(a) have been updated.

 

FORM 38.5(b)

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITHOUT RECOGNISED INTERMEDIARY STATUS, OR WITH RECOGNISED INTERMEDIARY STATUS BUT NOT DEALING IN A CLIENT-SERVING CAPACITY

 

1. KEY INFORMATION

 

Name of exempt principal trader

GOLDMAN SACHS & CO. LLC

Company dealt in

WILLIS TOWERS WATSON PLC

Class of relevant security to which the dealings being disclosed relate (Note1)

USD 0.000304635 ordinary shares

Date of dealing

19 October 2020

 

2. INTERESTS AND SHORT POSITIONS

 

(a) Interests and short positions (following dealing) in the class of relevant security dealt in  (Note 2)

 

 

Long

Short

 

Number

(%)

Number

(%)

(1) Relevant securities

526,639.912

(0.40)

298,666.912

(0.23)

(2) Derivatives (other than options)

50,873

(0.03)

374,217

(0.29)

(3) Options and agreements to purchase/sell

0

(0.00)

0

(0.00)

Total

577,512.912

(0.44)

672,883.912

(0.52)

 

(b) Interests and short positions in relevant securities of the company, other than the class dealt in  (Note 2)

 

Class of relevant security:

Long

Short

 

Number

(%)

Number

(%)

(1) Relevant securities

 

 

 

 

(2) Derivatives (other than options)

 

 

 

 

(3) Options and agreements to purchase/sell

 

 

 

 

Total

 

 

 

 

 

3.  DEALINGS (Note 3)

(a) Purchases and sales

 

Purchase/sale

Number of relevant securities

Price per unit  (Note 4)

Purchase

613

212.7100 USD

Purchase

3,871

212.7100 USD

Purchase

2

212.7100 USD

Purchase

91

212.7100 USD

Purchase

385

212.7100 USD

Purchase

12

212.8300 USD

Purchase

2

217.1300 USD

Purchase

1

217.1500 USD

Sale

100

212.6800 USD

Sale

409

212.7100 USD

Sale

1

212.7100 USD

Sale

777

212.7100 USD

Sale

329

212.7100 USD

Sale

576

212.7100 USD

Sale

4,405

212.7100 USD

Sale

20

212.7100 USD

Sale

10

214.9300 USD

Sale

90

214.9300 USD

Sale

13

214.9400 USD

Sale

87

214.9400 USD

Sale

85

214.9500 USD

Sale

100

214.9700 USD

Sale

3

215.0150 USD

Sale

4

215.0150 USD

Sale

8

215.0150 USD

Sale

100

215.0150 USD

Sale

15

215.1000 USD

Sale

85

215.1000 USD

Sale

100

215.2000 USD

Sale

100

215.2100 USD

Sale

100

215.2100 USD

Sale

95

215.3300 USD

Sale

5

215.3950 USD

Sale

100

215.3950 USD

Sale

100

215.4700 USD

Sale

100

215.4700 USD

Sale

9

215.4700 USD

Sale

1

215.4800 USD

Sale

100

215.4800 USD

Sale

100

215.4800 USD

Sale

21

215.4800 USD

Sale

10

215.5100 USD

Sale

1

215.5100 USD

Sale

99

215.5200 USD

Sale

100

215.5200 USD

Sale

70

215.5450 USD

Sale

92

215.5450 USD

Sale

8

215.5450 USD

Sale

89

215.5450 USD

Sale

57

215.6200 USD

Sale

79

215.6200 USD

Sale

21

215.6200 USD

Sale

43

215.6200 USD

Sale

10

215.6700 USD

Sale

100

215.6800 USD

Sale

90

215.7900 USD

Sale

25

215.8100 USD

Sale

100

215.8200 USD

Sale

100

215.9300 USD

Sale

15

215.9350 USD

Sale

60

215.9350 USD

Sale

10

215.9900 USD

Sale

90

215.9900 USD

Sale

100

216.0300 USD

Sale

100

216.0350 USD

Sale

5

216.0500 USD

Sale

48

216.0500 USD

Sale

47

216.0500 USD

Sale

50

216.0600 USD

Sale

50

216.0900 USD

Sale

50

216.1050 USD

Sale

100

216.1100 USD

Sale

152

216.1700 USD

Sale

48

216.2650 USD

Sale

100

216.3900 USD

Sale

20

216.3900 USD

Sale

180

216.4200 USD

Sale

7

216.4400 USD

Sale

10

216.5600 USD

Sale (Loan Adjust)

384

N/A

Sale (Loan Adjust)

9

N/A

Purchase (Loan Partial Return)

384

N/A

Sale (Loan New)

10,648

N/A

Purchase (Loan Full Return)

10,648

N/A

 

(b) Derivatives transactions (other than options transactions)

 

Product name, e.g. CFD

Nature of transaction  (Note 5)

Number of relevant securities  (Note 6)

Price per unit  (Note 4)

CFD

Reducing a short position

3,910

215.5601 USD

 

(c) Options transactions in respect of existing relevant securities

 

(i) Writing, selling, purchasing or varying

 

Product name,e.g. call option

Writing, selling,  purchasing, varying etc.

Number of securities to which the option relates  (Note 7)

Exercise price

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit  (Note 4)

 

 

 

 

 

 

 

 

(ii)  Exercising

 

Product name,e.g. call option

Number of securities

Exercise price per unit  (Note 4)

 

 

 

 

(d)  Other dealings (including transactions in respect of new securities)  (Note 3)

 

Nature of transaction  (Note 7)

Details

Price per unit (if applicable)  (Note 4)

 

 

 

 

4. OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.  If none, this should be stated. 

NONE

 

Is a Supplemental Form 8 attached? (Note 9)  YES

 

Date of disclosure

22 October 2020

Contact name

Kashif Rafiq and Papa Lette

Telephone number

+44(20) 7051 0547 / +44(20) 7774 7442

Name of offeree/offeror with which connected

WILLIS TOWERS WATSON PLC

Nature of connection (Note 9)

Advisor to Offeree

 

SUPPLEMENTAL FORM 38.5(b)

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DETAILS OF OPEN POSITIONS

 

OPEN POSITIONS (Note 1)

 

Product name,e.g. call option

Written or purchased

Number of relevant securities to which the option or derivative relates

Exercise price (Note 2)

Type, e.g. American, European etc.

Expiry date

Swap

Sold

185

0.0000

N/A

23/09/2021

Swap

Sold

273

0.0000

N/A

04/01/2021

Swap

Sold

44,335

0.0000

N/A

14/04/2021

Swap

Sold

69,482

0.0000

N/A

14/04/2021

 

Notes

1. Where there are open option positions or open derivative positions (except for CFDs), full details should be given. Full details of any existing agreements to purchase or to sell must also be given on this form.

2. For all prices and other monetary amounts, the currency must be stated.

For full details of disclosure requirements, see Rules 8 and 38.5 of the Rules. If in doubt, consult the Panel.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ISEEAXEAAEAEFFA